Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Abstract

At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.